For more than 50 years, the NCI has supported a clinical trials infrastructure [the NCI National Clinical Trials Cooperative Group Program (CTCGP)] to conduct large-scale, clinical treatment trials across the nation. As part of its effort to take advantage of new discoveries in oncologic sciences, the NCI asked the Institute of Medicine (lOM) in 2009 to review the NCI-sponsored CTCGP. Based on the lOM review recommendations, as well as additional input received from stakeholders across the oncology community, the NCI has developed a comprehensive plan to transform the previous CTCGP that funded several separate organizations conducting cancer treatment trials into a new consolidated and integrated Program referred to as the NCI National Clinical Trials Network (NCTN). The University of Pittsburgh Cancer Institute (UPCI) has been an NCI-designated Comprehensive Cancer Center since 1990. The UPCI has led ably and participated in several NCI CTCGPs, including ECOG, NSABP, RTOG, GOG, and ACOSOG. The UPCI now plans to participate under the new NCI NCTN as a Lead Academic Site. We propose to participate in NCTN as a Network Lead Academic Participating Site with the following Specific Aims: 1. To enhance the quality off scientific and administrative leadership in the development and conduct of clinical trials across the NCTN;2. To continue and improve our accrual to multi-center clinical trials at UPCI;To continue and improve processes for rapid activation of new trials at UPCI.

Public Health Relevance

As a Lead Academic Site of the NCI National Cancer Network, the UPCI intends to leverage its historical leadership in the cancer cooperative groups, as well as its sophisticated and vibrant clinical research programs, to reduce the burden of cancer through assistance in the conduct of large, multicenter, scientifically sound, important cancer clinical trials with the potential to change the standard of cancer care in the United States and worldwide.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180844-01
Application #
8605956
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-24
Project End
2019-02-28
Budget Start
2014-04-24
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Belani, Chandra P; Dahlberg, Suzanne E; Rudin, Charles M et al. (2016) Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer 122:2371-8
Kent, Michael S; Mandrekar, Sumithra J; Landreneau, Rodney et al. (2016) Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance). Ann Thorac Surg 102:230-8
Langer, Corey J; Socinski, Mark A; Patel, Jyoti D et al. (2016) Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials. Am J Clin Oncol 39:441-7
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2016) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol :
Cecchini, Reena S; Swain, Sandra M; Costantino, Joseph P et al. (2016) Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. Cancer Epidemiol Biomarkers Prev 25:51-9
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Solin, Lawrence J; Gray, Robert; Hughes, Lorie L et al. (2015) Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. J Clin Oncol 33:3938-44
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2015) Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 373:2005-14
Villaruz, Liza C; Huang, Grace; Romkes, Marjorie et al. (2015) MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clin Epigenetics 7:58
Pogue-Geile, Katherine L; Song, Nan; Jeong, Jong-Hyeon et al. (2015) Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol 33:1340-7

Showing the most recent 10 out of 24 publications